ERBB2 and breast cancer: The PERMEATE trial involving 78 patients with HER2-positive BC with brain metastases revealed that, for radiotherapy-naive and radiotherapy-resistant cohorts receiving pyrotinib plus capecitabine, the intracranial ORRs were 74.6% (95% CI 61.6–85.0) and 42.1% (95% CI 20.3–66.5), respectively, and median PFS was 11.3 months (95% CI 7.7–14.6) and 5.6 months (95% CI 3.4–10.0), respectively.